4.2 Review

PILOT STUDY TO DESCRIBE THE TRAJECTORY OF SYMPTOMS AND ADAPTIVE STRATEGIES OF ADULTS LIVING WITH LOW-GRADE GLIOMA

Journal

SEMINARS IN ONCOLOGY NURSING
Volume 34, Issue 5, Pages 472-485

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.soncn.2018.10.006

Keywords

glioma; symptoms; quality of life; adaptive leadership

Funding

  1. ADAPT Center (Center for Adaptive Leadership in Symptom Science) - National Institutes of Health/National Institute of Nursing Research award [1P30-NR014139]
  2. NATIONAL INSTITUTE OF NURSING RESEARCH [P30NR014139] Funding Source: NIH RePORTER

Ask authors/readers for more resources

OBJECTIVES: To describe the adaptability to the patterns in symptoms and quality of life (QoL) during 6 months post low-grade glioma diagnosis by valid and reliable tools; to identify through qualitative interviews patient/provider adaptive techniques and strategies; and to assess associations among patient characteristics, symptoms and QoL, and adaptive techniques or strategies. DATA SOURCES: Demographic, clinical and pathologic data from medical records. Validated instruments that assess QoL, fatigue, depression, and distress were completed at 2, 4, and 6 months post diagnosis. Qualitative interviews identifying the symptoms, challenges, adaptive techniques and strategies were conducted at 4 and 6 months. CONCLUSION: The most frequently used adaptive strategies included: obtaining community support (87%), managing expectations (73%) and support systems (67%), and seeking out knowledge about physical (67%) and behavioral symptoms (53%). Seizures were reported with IDH1(mut) (11%) but not IDH1(wildtype) Patients with either IDH1(mut) or TERTmut consistently reported lower QoL and higher distress, depression, and fatigue scores. IDH1/TERTmut may be related to lower QoL because of IDH1(mut)-related seizures. IMPLICATIONS FOR NURSING PRACTICE: Findings provide a list of adaptive strategies and characteristics to address the problems and symptoms that may improve overall QoL in patients with low-grade glioma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

Mallika P. Patel, Sarah Woodring, Dina M. Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, Frances McSherry, Eric S. Lipp, Elizabeth Miller, Katherine B. Peters, Mary Lou Affronti

SUPPORTIVE CARE IN CANCER (2020)

Article Integrative & Complementary Medicine

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population

Dina M. Randazzo, Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, Sarah Woodring, Susan Boulton, Annick Desjardins, David M. Ashley, Henry S. Friedman, Katherine B. Peters

COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE (2019)

Article Clinical Neurology

Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults

Christian Thomas, Annika Wefers, Susanne Bens, Karolina Nemes, Abbas Agaimy, Florian Oyen, Silke Vogelgesang, Fausto J. Rodriguez, Francesca M. Brett, Roger McLendon, Istvan Bodi, Fanny Burel-Vandenbos, Kathy Keyvani, Stefan Tippelt, Frantz R. Poulsen, Eric S. Lipp, Caterina Giannini, Guido Reifenberger, Klaus Kuchelmeister, Torsten Pietsch, Uwe Kordes, Reiner Siebert, Michael C. Fruehwald, Pascal D. Johann, Martin Sill, Marcel Kool, Andreas von Deimling, Werner Paulus, Martin Hasselblatt

ACTA NEUROPATHOLOGICA (2020)

Article Oncology

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series

Mallika P. Patel, John P. Kirkpatrick, Margaret O. Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S. Miller, Annick Desjardins, Dina Randazzo, Henry S. Friedman, David M. Ashley, Katherine B. Peters

JOURNAL OF NEURO-ONCOLOGY (2020)

Article Oncology

The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts

Alex Broom, Katherine Kenny, Alexander Page, Nicole Cort, Eric S. Lipp, Aaron C. Tan, David M. Ashley, Kyle M. Walsh, Mustafa Khasraw

CLINICAL CANCER RESEARCH (2020)

Article Multidisciplinary Sciences

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Matthias Gromeier, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, Hai Yan, Yiping He, Annick Desjardins, James E. Herndon, Frederick S. Varn, Roel G. Verhaak, Junfei Zhao, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, Frances McSherry, Andrea M. Muscat, Eric S. Lipp, Smita K. Nair, Mustafa Khasraw, Katherine B. Peters, Dina Randazzo, John H. Sampson, Roger E. McLendon, Darell D. Bigner, David M. Ashley

Summary: The study found that low tumor mutation burden is associated with longer survival after immunotherapy in recurrent glioblastoma patients, and this relationship is related to inflammatory gene signatures, which evolves upon recurrence.

NATURE COMMUNICATIONS (2021)

Article Oncology

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis

Jessica W. Lee, John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina M. Randazzo, Henry S. Friedman, David M. Ashley, Katherine B. Peters, Margaret O. Johnson

Summary: In this study of older patients with GBM, age and KPS were associated with the choice between short-course and standard RT. Both regimens showed similar overall survival, but some patients experienced worsening symptoms and discontinued treatment during RT. Further research into predictors of RT completion and survival could help improve adjuvant therapy and supportive care for older patients.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial

Katherine B. Peters, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E. Herndon, Elizabeth S. Miller, Maria W. Freeman, Dina M. Randazzo, Annick Desjardins, Henry S. Friedman

Summary: A placebo-controlled, double-blind study showed that low-dose naltrexone (LDN) did not have a significant impact on quality of life and fatigue in patients with high-grade glioma (HGG) during concurrent chemotherapy and radiation therapy.

SUPPORTIVE CARE IN CANCER (2022)

Article Clinical Neurology

Availability and role of clinical pharmacists in ambulatory neuro-oncology

Mallika P. Patel, Eric S. Lipp, Elizabeth S. Miller, Patrick N. Healy, James E. Herndon, Katherine B. Peters

Summary: The study found that most clinical members in the surveyed neuro-oncology community do not have the support or expertise of dedicated neuro-oncology pharmacists, despite the demanding nature of their outpatient practices.

NEURO-ONCOLOGY PRACTICE (2022)

Article Clinical Neurology

Patterns of care in adult histone mutant gliomas: Results of an international survey

Alexander Yuile, Mustafa Khasraw, Justin T. Low, Kyle M. Walsh, Eric Lipp, Joanne Sy, Laveniya Satgunaseelan, Marina Ann Kastelan, Madhawa De Silva, Adrian Lee, Helen Wheeler

Summary: This study investigates the current patterns of clinical practice for histone mutant gliomas (HMG) in Australia and the United States (US). The results show variations in testing methods and treatment approaches for HMG patients, and the knowledge of H3 mutations impacts the management of these gliomas, particularly during recurrence.

NEURO-ONCOLOGY PRACTICE (2022)

Article Hematology

Determining venous thromboembolism risk in patients with adult-type diffuse glioma

Kirsten Bell Burdett, Dusten Unruh, Michael Drumm, Alicia Steffens, Jonathan Lamano, Jonathan Judkins, Margaret Schwartz, Rodrigo Javier, Christina Amidei, Eric S. Lipp, Katherine B. Peters, Albert Lai, Blaine S. C. Eldred, Amy B. Heimberger, Kathleen McCortney, Denise M. Scholtens, Craig Horbinski

Summary: The study developed a VTE prediction tool to improve care for adult-type diffuse glioma patients, incorporating clinical, blood-based, histologic, and molecular markers. Analysis of data from 258 newly diagnosed patients revealed that tumor expression of TF and PDPN correlated with VTE, and circulating TF and D-dimers correlated with VTE risk. Several factors, including past VTE history, hypertension, asthma, white blood cell count, WHO tumor grade, patient age, and body mass index, predicted increased VTE risk in newly diagnosed glioma patients. Conversely, IDH mutation, hypothyroidism, and MGMT promoter methylation predicted reduced VTE risk.

BLOOD (2023)

Article Oncology

Use of Trametinib in Children and Young Adults With Progressive Low-grade Glioma and Glioneuronal Tumors

Emily Hanzlik, Bridget Archambault, Mays El-Dairi, Kristin Schroeder, Mallika P. Patel, Eric S. Lipp, Katherine B. Peters, David M. Ashley, Daniel Landi

Summary: A retrospective chart review showed that trametinib is effective and well-tolerated in patients with progressive low-grade glioma. The best radiographic response was seen after a longer duration of therapy, and patients with optic pathway lesions showed stable to improved vision while on treatment.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2023)

Article Clinical Neurology

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients

Dina M. Randazzo, Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Elizabeth S. Miller, Sarah Woodring, Patrick Healy, Jennifer Jackman, Brian Crouch, Annick Desjardins, David M. Ashley, Henry S. Friedman, Katherine B. Peters

Summary: This study aimed to investigate the association between spiritual well-being (SWB) and health-related quality of life (HRQoL) in primary brain tumor patients. The results showed that higher SWB was associated with better HRQoL, emphasizing the importance of spiritual aspects in strategies to improve HRQoL in primary brain tumor patients.

NEURO-ONCOLOGY PRACTICE (2021)

Letter Oncology

Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort

Erica Shen, Margaret O. Johnson, Jessica W. Lee, Eric S. Lipp, Dina M. Randazzo, Annick Desjardins, Roger E. McLendon, Henry S. Friedman, David M. Ashley, John P. Kirkpatrick, Katherine B. Peters, Kyle M. Walsh

NEURO-ONCOLOGY ADVANCES (2019)

Article Public, Environmental & Occupational Health

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice

Annick Desjardins, James E. Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, John H. Sampson, Dina Randazzo, Nicolas Sommer, Allan H. Friedman, Henry S. Friedman

HEALTH SCIENCE REPORTS (2019)

No Data Available